Comparison of levetiracetam and phenobarbitone for treatment of seizures in newborns

Assessment Of Efficacy And Safety Of Levetiracetam Vs Phenobarbitone As First Line Management In Neonatal Seizures- A Randomized Controlled Study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/107491

Enrollment

Registered

2026-04-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G408- Other epilepsy and recurrent seizures

Interventions

Intervention1: Phenobarbitone and Levetiracetam: Phenobarbitone intravenous, @20mg/kg loading dose upto total of 40mg/kg if seizure not controlled Levetiracetam intravenous, @20mg/kg loading dose upt

Eligibility

Inclusion criteria

Inclusion criteria: All neonates with neonatal seizures admitted in NICU at Sharda Hospital Greater Noida.

Exclusion criteria

Exclusion criteria: Seizures due to short term metabolic causes like hypoglycemia, hypocalcemia, hypomagnesemia

Design outcomes

Primary

Measure	Time frame
The proportion of neonates achieving cessation of seizures following the maximum permissible dose of each drugTimepoint: 24 hours	—

Secondary

Measure	Time frame
Proportion of patients experiencing adverse events with each drugTimepoint: during hospital stay	—

Countries

India

Contacts

Public ContactDr Adeeba Ahmed

Sharda University

meenakshibothra@gmail.com87005 09704

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026